Maria B Monteiro1, Susanne Ramm1,2, Vidya Chandrasekaran1, Sarah A Boswell1, Elijah J Weber3, Kevin A Lidberg3, Edward J Kelly3, Vishal S Vaidya4,2,5. 1. Harvard Program in Therapeutic Science, Harvard Medical School Laboratory of Systems Pharmacology, Boston, Massachusetts. 2. Renal Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. 3. Department of Pharmaceutics, University of Washington, Seattle, Washington; and. 4. Harvard Program in Therapeutic Science, Harvard Medical School Laboratory of Systems Pharmacology, Boston, Massachusetts; vvaidya@bwh.harvard.edu. 5. Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Abstract
BACKGROUND: The death of epithelial cells in the proximal tubules is thought to be the primary cause of AKI, but epithelial cells that survive kidney injury have a remarkable ability to proliferate. Because proximal tubular epithelial cells play a predominant role in kidney regeneration after damage, a potential approach to treat AKI is to discover regenerative therapeutics capable of stimulating proliferation of these cells. METHODS: We conducted a high-throughput phenotypic screen using 1902 biologically active compounds to identify new molecules that promote proliferation of primary human proximal tubular epithelial cells in vitro. RESULTS: The primary screen identified 129 compounds that stimulated tubular epithelial cell proliferation. A secondary screen against these compounds over a range of four doses confirmed that eight resulted in a significant increase in cell number and incorporation of the modified thymidine analog EdU (indicating actively proliferating cells), compared with control conditions. These eight compounds also stimulated tubular cell proliferation in vitro after damage induced by hypoxia, cadmium chloride, cyclosporin A, or polymyxin B. ID-8, an inhibitor of dual-specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A), was the top candidate identified as having a robust proproliferative effect in two-dimensional culture models as well as a microphysiologic, three-dimensional cell culture system. Target engagement and genetic knockdown studies and RNA sequencing confirmed binding of ID-8 to DYRK1A and upregulation of cyclins and other cell cycle regulators, leading to epithelial cell proliferation. CONCLUSIONS: We have identified a potential first-in-class compound that stimulates human kidney tubular epithelial cell proliferation after acute damage in vitro.
BACKGROUND: The death of epithelial cells in the proximal tubules is thought to be the primary cause of AKI, but epithelial cells that survive kidney injury have a remarkable ability to proliferate. Because proximal tubular epithelial cells play a predominant role in kidney regeneration after damage, a potential approach to treat AKI is to discover regenerative therapeutics capable of stimulating proliferation of these cells. METHODS: We conducted a high-throughput phenotypic screen using 1902 biologically active compounds to identify new molecules that promote proliferation of primary human proximal tubular epithelial cells in vitro. RESULTS: The primary screen identified 129 compounds that stimulated tubular epithelial cell proliferation. A secondary screen against these compounds over a range of four doses confirmed that eight resulted in a significant increase in cell number and incorporation of the modified thymidine analog EdU (indicating actively proliferating cells), compared with control conditions. These eight compounds also stimulated tubular cell proliferation in vitro after damage induced by hypoxia, cadmium chloride, cyclosporin A, or polymyxin B. ID-8, an inhibitor of dual-specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A), was the top candidate identified as having a robust proproliferative effect in two-dimensional culture models as well as a microphysiologic, three-dimensional cell culture system. Target engagement and genetic knockdown studies and RNA sequencing confirmed binding of ID-8 to DYRK1A and upregulation of cyclins and other cell cycle regulators, leading to epithelial cell proliferation. CONCLUSIONS: We have identified a potential first-in-class compound that stimulates human kidney tubular epithelial cell proliferation after acute damage in vitro.
Authors: Miles A Fabian; William H Biggs; Daniel K Treiber; Corey E Atteridge; Mihai D Azimioara; Michael G Benedetti; Todd A Carter; Pietro Ciceri; Philip T Edeen; Mark Floyd; Julia M Ford; Margaret Galvin; Jay L Gerlach; Robert M Grotzfeld; Sanna Herrgard; Darren E Insko; Michael A Insko; Andiliy G Lai; Jean-Michel Lélias; Shamal A Mehta; Zdravko V Milanov; Anne Marie Velasco; Lisa M Wodicka; Hitesh K Patel; Patrick P Zarrinkar; David J Lockhart Journal: Nat Biotechnol Date: 2005-02-13 Impact factor: 54.908
Authors: Benjamin D Humphreys; Suzanne Czerniak; Derek P DiRocco; Wirasat Hasnain; Rabia Cheema; Joseph V Bonventre Journal: Proc Natl Acad Sci U S A Date: 2011-05-16 Impact factor: 11.205
Authors: Melanie Adler; Susanne Ramm; Marc Hafner; Jeremy L Muhlich; Esther Maria Gottwald; Elijah Weber; Alenka Jaklic; Amrendra Kumar Ajay; Daniel Svoboda; Scott Auerbach; Edward J Kelly; Jonathan Himmelfarb; Vishal S Vaidya Journal: J Am Soc Nephrol Date: 2015-08-10 Impact factor: 10.121
Authors: Segav Demirjian; Gorav Ailawadi; Martin Polinsky; Dani Bitran; Shuli Silberman; Stanton Keith Shernan; Michel Burnier; Marta Hamilton; Elizabeth Squiers; Shai Erlich; Daniel Rothenstein; Samina Khan; Lakhmir S Chawla Journal: Kidney Int Rep Date: 2017-04-25
Authors: Vishal Deshmukh; Tim Seo; Alyssa L O'Green; Maureen Ibanez; Brian Hofilena; Sunil Kc; Joshua Stewart; Luis Dellamary; Kevin Chiu; Abdullah Ghias; Charlene Barroga; Sarah Kennedy; Jeyanesh Tambiah; John Hood; Yusuf Yazici Journal: J Orthop Res Date: 2020-11-18 Impact factor: 3.494